Tolerx, Inc.
http://www.tolerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tolerx, Inc.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.
Axsome Succeeds In Narcolepsy Phase III, But Is That Enough?
Analysts say reboxetine looks approvable for cataplexy related to narcolepsy, but debate how broadly the drug may be adopted in a generic-laden therapeutic space.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.
Adopt Unilever Model, Tech To Prevent ‘India Plus One’ Situation – CRDMO CXOs
CRDMO CXOs sketch a promising landscape for the Indian industry, highlighting technology, scale and talent, particularly millennials and Gen Z, as key factors in a SWOT analysis - while cautioning that a global ‘China plus one’ strategy could turn to a ‘India plus one’ too.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice